200 Years of Quality: Building Trust in Medicines and Supplements

Ronald T. Piervincenzi, Ph.D. Chief Executive Officer, USP

Anthony Lakavage, JD Secretary, USP Convention & Board of Trustees Sr Vice President, Global External Affairs

Loma Linda University Institute for Health Policy and Leadership October 14, 2020



Agenda



▶ Who is USP?

- Responding to the challenges surfaced by the COVID-19 pandemic
 - Medicines supply chain resilience
 - Strengthening the supply of trusted, quality COVID-19 vaccines and treatments
- Expanding the quality of dietary supplements
- Facilitated Q & A





Who is USP?

USP Mission



To improve global health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods.



Responding to today's public health challenges through coordinated standards, advocacy, and capability building



 Standards: To be a definitive source of standards for the supply of quality medicines

Advocacy: To be the global institutional leader advancing the supply of quality medicines

Capability Building: To be a leading provider of services that

leading provider of services that advance the supply of quality medicines to improve the health and well-being of people and patients



Our people – USP's global staff and volunteers





6 © 2020 USP

Evolving standards to address quality paradigm shifts



- Leading standardization of new scientific approaches (e.g., risk-based, performance-based, flexible)
- Providing knowledge on more-complicated and emerging modalities
- Facilitating establishing equivalence for evolving analytical and advanced manufacturing technologies
- Ensuring our standards stay relevant and help improve the supply of quality medicines



Being a definitive source of standards for the supply of quality medicines

More than 9,000 USP Standards provide quality benchmarks across the supply chain



- Standards for medicines, excipients, and APIs in USP-NF
 - 350 General Chapters
 - 4,900 product-specific monographs
 - 3,500 physical reference standards
- More than 1,200 standards for dietary supplements in the Dietary Supplements Compendium (DSC)
- Nearly 1300 standards for Food Ingredients in Food Chemicals Codex (FCC)
- More than 500 standards for biologics
- About 300 Healthcare Quality & Safety Standards, including compounding, nomenclature and labeling, safety, etc.



Standards

USP standards are utilized in over 150 countries 200

The standard of trust

USP Reference Standards were shipped to over 22,000 entities in FY19

Units of USP Reference Standards shipped globally (Top 10 countries labeled, 2015-2019)



Advocating for the supply of quality medicines worldwide



- Generating data to inform policy making through the USP Quality Institute (e.g., AMR, excipient quality, and procurement policies)
- Engaging in public dialogues to provide USP's expertise and perspective in the interest of better policy and outcomes
- Collaboration with stakeholders and USP
 Convention members to help inform and drive change
- Supporting the supply of and public trust in vaccines and treatments to address COVID-19
- Longstanding regulatory engagement with pharmacopeias and governments worldwide

Being the global institutional leader advancing the supply of quality medicines

Advocacy

Our global engagement and advocacy is powered by more than 490 USP Convention Organizations





Education, training, and verification services to build stakeholder capabilities in advancing medicines quality



- Helping global regulators and manufacturers acquire the required skills, knowledge, tools or enabling environment to advance access to quality medicines and medical products
- Verification services for industry (e.g., dietary supplements, excipients)
- Facilitating the adoption of new manufacturing technologies (e.g., continuous manufacturing)
- Custom tailored standards and tools for analytical research & development (e.g., impurities)
- Donor funded work to support regulatory and industry capability building in LMICs



People Quality Digital Investment and Sustainability

Being a leading provider of services that advance the supply of quality medicines to improve the health and well-being of people and patients



Responding to today's public health challenges

USP's work to address challenges surfaced by the COVID-19 pandemic





USP has published a white paper identifying key actions to secure a more resilient supply chain

20Cusp. The standard of trust

- Foster more, not less, supply chain diversity
- Invest in more manufacturing capacity for critical medicines (e.g., continuous manufacturing)
- Enable more transparency and data sharing
- Conduct crisis contingency planning and action
- Strengthen regulatory systems and quality assurance globally

https://www.usp.org/sites/default/files/usp/document/our-impact/covid-19/global-policy-supplychain.pdf



We are generating proactive insights on risk in the upstream supply chain



- We created the USP Medicine Supply Map as an early warning system to identify, characterize and quantify risk in the upstream pharmaceutical supply chain
- Data model links across 10+ datasets and dozens of data elements, including USP's proprietary insights
- "In-the-field" data gathering, including through USP's subject matter expert network
- More than 1 million medicines globally included
- Graph-based data model is capable of tracking quality issues up the supply chain



Example: there is a need for greater upstream supply chain transparency



Information listed on U.S. approved human prescription drug labels (N=40,178)



Source: USP analysis of DailyMed

1 Includes 'Analysis', 'FDF Manufacturer', 'Manufacturer', Particle size reduction', "Positron Emission Tomography Drug Production', 'Recovery', 'Sterilize', 'Transfill' 2 'Label, Relabel, Pack, Repack''

- While approval information is known, we don't know how many are manufacturing the medicine/API
- All labels specify ANDA filer, an entity responsible for the drug's quality. However, manufacturing is often done by a different entity than the filer
- While manufacturers are required and do report suppliers to U.S. FDA, also sharing supply chain information publicly could help providers proactively safeguard patient health. (e.g., when a safety issue is identified with an API manufacturer, providers will have on-hand information about impacted brands)

17 © 2019 USP

Agile approach to support COVID-19 vaccines and treatments







Improve access to innovative vaccines through reductions in development times and increased scalability



Provide a safeguard against poor quality vaccines, ensuring public trust and safety USP standards are publicly available tools that vaccine manufacturers can use to help answer questions such as:



=>]]

Ingredients

How can I be sure my ingredients are appropriate for my vaccine process? Are they pure? Is there a consistent supply from a reliable supplier?

Containers

Will the items used, such as syringes, make it easy for the patient to get the vaccine? Do they leak? Does the container react with the vaccine and change its quality?

Sterility

Is the vaccine sterile? For multi-dose vials, is the antimicrobial agent effective?

4 Labeling

Does the label clearly and accurately indicate the name, dose and how it should be administered?

Packaging and distribution

Is the vaccine packaged correctly to avoid damage and temperature fluctuations during storage and shipping?

* List not exhaustive

usp.org/trust-accelerated

Building stakeholder capabilities to support development of COVID-19 vaccines and treatments



- Launching the USP Trust Accelerated Program to help speed development of quality COVID-19 treatments and vaccines
- Convening a Vaccine Advisory Group to monitor trends, interpret, refine and prioritize USP's efforts to facilitate global access
- Education and training opportunities from hot topics webinars to industry co-developed courses addressing key vaccine challenges
- Free-of-charge technical assistance to support development and scale-up of potential vaccine candidates
- Convening stakeholders on building and maintaining trust in COVID-19 vaccines. advocating for quality assured vaccines



COVID-19 vaccines and treatments

Scientists and manufacturers can leverage free USP technical expertise and resources to support their path to regulatory acceptance.

See hov



Expanding the supply of quality dietary supplements

Millions of Americans take dietary supplements







1. Council for Responsible Nutrition. (2019). 2019 CRN Consumer Survey on Dietary Supplements. www.crnusa.org/CRNConsumerSurvey

2. Advisory Board. (2019, February 13). FDA says it's cracking down on the \$40B dietary supplement industry—but is it just a 'big PR push'? www.advisory.com/daily-briefing/2019/02/13/fda-supplements 3. U.S. Food & Drug Administration. (2019, October 2). Tainted products marketed as dietary supplements. www.accessdata.fda.gov/scripts/sda/sdnavigation.cfm?sd=tainted_supplements_cder

21

Overview of dietary supplement regulation in the U.S.

- Dietary Supplements Health Education Act (DSHEA-1994) defines supplements as foods containing dietary ingredients, including:
 - a vitamin; mineral; amino acid
 - an herb or other botanical;
 - a dietary substance for use by man to supplement the diet;
 - a concentrate, metabolite, constituent, and/or extract
- Dietary supplements cannot be marketed for use to treat, mitigate, or cure a disease.
- An exclusion clause prohibits drugs that were the subject of clinical studies before DSHEA to be marketed as dietary supplements
- Dietary supplements do not require pre-market approval, but the FDA must be notified before marketing of "new" dietary ingredients





USP helped form the Dietary Supplements Quality Collaborative (DSQC) to expand the safety and quality of supplements



Steering Committee

Members



DSQC delivers its mission through three pillars





DSOC Advancing the Quality and Safety of Dietary Supplements

24 © 2020 USP

There is a greater need to advocate for greater transparency and quality of supplements



- The supplement industry has grown from a few thousand to well over 50,000 products¹
- 25 years after Congress enacted DSHEA, the greatest weakness is FDA's inability to "see" into the marketplace
- FDA has limited means of knowing
 - What products are in the market
 - Which companies are producing supplements
 - What ingredients they contain

1. Advisory Board. (2019, February 13). FDA says it's cracking down on the \$40B dietary supplement industry—but is it just a 'big PR push'? www.advisory.com/daily-briefing/2019/02/13/fda-supplements



USP launched the Dietary Supplement Verification Program to strengthen public trust and help ensure the quality of supplements

The USP Verified Mark on a dietary supplement label indicates that the product:

- Contains the ingredients listed on the label, in the declared potency and amounts.
- Does not contain harmful levels of specified contaminants.
- Will break down and release into the body within a specified amount of time.
- Has been made according to FDA current Good Manufacturing Practices using sanitary and well-controlled procedures.



Public quality standards help strengthen stakeholder trust across the supply chain



Industry

Dietary supplement and ingredient manufactures produce quality products



Practitioner/Patient

Uphold practitioner and patient confidence in the quality of their supplements



Governments

Regulators ensure quality products reach consumers



Facilitated Q & A

Stay Connected

@RonPiervincenzi | www.usp.org | @USPharmacopeia

